Cone Rod Dystrophy Market
- 2026 年市場規模
- USD 148.6 Mn
- 2033 年預估規模
- USD 237.8 Mn
- 年複合成長率 CAGR
- 7%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Cone Rod Dystrophy Market, By Disease Type (Cone-Rod Dystrophy and Rod-Cone Dystrophy), By Diagnosis (Genetic Testing, Electroretinography (ERG), Optical Coherence Tomography (OCT), Fundus Autofluorescence (FAF), and Others), By Treatment (Supportive Care, Pharmacological Therapy, Gene Therapy, Cell Therapy, and Retinal Prostheses and Visual Aids), By End User (Hospitals, Ophthalmology Clinics, Specialty Eye Centers, Research Institutes, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
報告摘要
The global cone rod dystrophy market is estimated to be valued at USD 148.6 Mn in 2026 and is expected to reach USD 237.8 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 7% from 2026 to 2033. Cone-rod dystrophy (CRD) is a group of rare inherited disorders in which the retina's cones photoreceptors deteriorate followed by rods, leading to the gradual loss of central and color vision and visual acuity, then loss of peripheral vision. Cone-rod dystrophy can result from a wide range of mutations affecting over 30 genes, such as the ABCA4, RPGR and CRX gene, and is inherited in autosomal dominant, recessive or X-linked patterns. With an estimated worldwide prevalence between 1 in 30,000 and 1 in 40,000 people, CRD represents an area of significant unmet need.
The cone rod dystrophy market comprises several segments including diagnostic, supportive care and low vision rehabilitation technologies, in addition to nascent but advancing gene and cell therapies that represent novel advanced treatment options. The market growth is stimulated by rising rates of genetic diagnosis, expanded inherited retinal disease clinical trials, support from various orphan drug initiatives and innovation in ocular gene therapies that enhance chances of prompt diagnosis and disease-modifying therapies for patients.
Market Dynamics
The global cone rod dystrophy market is driven by expanding gene therapies pipeline, growing adoption of genetic testing for early diagnosis of disease, and increasing R&D investment by the pharmaceutical companies in the development of targeted therapy and innovative approaches in the area of precision medicine in rare inherited retinal disorders. The rise in adoption of novel technologies like next-generation sequencing, the launch of several orphan drug incentives and ongoing clinical development of a comprehensive portfolio of cell and gene therapies have boosted the potential of early identification and treatment of cone rod dystrophy and supported the accelerated introduction of disease-modifying therapeutics.
However, a number of constraints are present in the market, such as high heterogeneity of the underlying genetic mutations in the disease population, high costs of development and treatment and the complexities involved in assembling appropriate cohort size samples from the limited CRD population in clinical trials. Nevertheless, developments such as CRISPR-based technology, broadening research in identifying effective biomarkers, along with expanding strategic alliances amongst biopharmaceutical firms and public research bodies will offer new opportunities for growth in cone rod dystrophy market.
Key Features of the Study
• This report provides in-depth analysis of the global cone rod dystrophy market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cone rod dystrophy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, JCyte, MeiraGTx, Spark Therapeutics, Ocugen, Inc., ProQR Therapeutics, Alkeus Pharmaceuticals, and BlueRock Therapeutics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cone rod dystrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cone rod dystrophy market
Market Segmentation
• Disease Type Insights (Revenue, USD Mn, 2021 - 2033)
o Cone-Rod Dystrophy
o Rod-Cone Dystrophy
• Diagnosis Insights (Revenue, USD Mn, 2021 - 2033)
o Genetic Testing
o Electroretinography (ERG)
o Optical Coherence Tomography (OCT)
o Fundus Autofluorescence (FAF)
o Others
• Treatment Insights (Revenue, USD Mn, 2021 - 2033)
o Supportive Care
o Pharmacological Therapy
o Gene Therapy
o Cell Therapy
o Retinal Prostheses and Visual Aids
• End User Insights (Revenue, USD Mn, 2021 - 2033)
o Hospitals
o Ophthalmology Clinics
o Specialty Eye Centers
o Research Institutes
o Others
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o SparingVision
o Beacon Therapeutics
o Nanoscope Therapeutics
o JCyte
o MeiraGTx
o Spark Therapeutics
o Ocugen, Inc.
o ProQR Therapeutics
o Alkeus Pharmaceuticals
o BlueRock Therapeutics
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Global Cone Rod Dystrophy Market, By Disease Type
Global Cone Rod Dystrophy Market, By Diagnosis
Global Cone Rod Dystrophy Market, By Treatment
Global Cone Rod Dystrophy Market, By End User
Global Cone Rod Dystrophy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Disease Type Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Industry Trends
4. Global Cone Rod Dystrophy Market, By Disease Type, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Cone-Rod Dystrophy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Rod-Cone Dystrophy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Cone Rod Dystrophy Market, By Diagnosis, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Genetic Testing
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Electroretinography (ERG)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Optical Coherence Tomography (OCT)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Fundus Autofluorescence (FAF)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Cone Rod Dystrophy Market, By Treatment, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Supportive Care
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Pharmacological Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Gene Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Cell Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Retinal Prostheses and Visual Aids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Cone Rod Dystrophy Market, By End User, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Ophthalmology Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Specialty Eye Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Research Institutes
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Cone Rod Dystrophy Market, By Region, 2021 - 2033, Value (USD Mn)
o Introduction
Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
Regional Trends
o North America
Introduction
Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o Germany
o U.K.
o Spain
o France
o Italy
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
o South Africa
o North Africa
o Central Africa
9. Competitive Landscape
o SparingVision
Company Highlights
Disease Type Portfolio
Key Developments
Financial Performance
Strategies
o Beacon Therapeutics
Company Highlights
Disease Type Portfolio
Key Developments
Financial Performance
Strategies
o Nanoscope Therapeutics
Company Highlights
Disease Type Portfolio
Key Developments
Financial Performance
Strategies
o JCyte
Company Highlights
Disease Type Portfolio
Key Developments
Financial Performance
Strategies
o MeiraGTx
Company Highlights
Disease Type Portfolio
Key Developments
Financial Performance
Strategies
o Spark Therapeutics
Company Highlights
Disease Type Portfolio
Key Developments
Financial Performance
Strategies
o Ocugen, Inc.
Company Highlights
Disease Type Portfolio
Key Developments
Financial Performance
Strategies
o ProQR Therapeutics
Company Highlights
Disease Type Portfolio
Key Developments
Financial Performance
Strategies
o Alkeus Pharmaceuticals
Company Highlights
Disease Type Portfolio
Key Developments
Financial Performance
Strategies
o BlueRock Therapeutics
Company Highlights
Disease Type Portfolio
Key Developments
Financial Performance
Strategies
10. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
11. References and Research Methodology
o References
o Research Methodology
o About us
*Browse 32 market data tables and 28 figures on ‘Cone Rod Dystrophy Market' - Global forecast to 2033
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們